NCT05320926 Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial
| NCT ID | NCT05320926 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Ischemic Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,744 participants |
| Start Date | 2022-07-26 |
| Primary Completion | 2028-07-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,744 participants in total. It began in 2022-07-26 with a primary completion date of 2028-07-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Previous randomized clinical trials have deomonstrated the efficacy and safety of short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), however, the single antiplatelet agent to be maintained after short-term DAPT was different. Therefore, which antiplatelet agent to be maintained after short-term DAPT needs further invstigations.
Eligibility Criteria
Inclusion Criteria: 1. Patients ≥19 years 2. Patients who received new generation zotarolimus-eluting Onyx stents implantation for treating ischemic heart disease 3. Provision of informed consent Exclusion Criteria: 1. Age ≥ 85 years 2. Acute myocardial infarction 2\. Left main bifurcation requiring 2-stent technique 3. Pregnant women or women with potential childbearing 4. Life expectancy \< 1 year 5. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator 6. Inability to understand or read the informed consent
Contact & Investigator
Byeong-Keuk Kim
PRINCIPAL INVESTIGATOR
Severance Cardiovascular Hospital, Yonsei University Health System
Frequently Asked Questions
Who can join the NCT05320926 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 84 Years, studying Ischemic Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05320926 currently recruiting?
Yes, NCT05320926 is actively recruiting participants. Contact the research team at kimbk@yuhs.ac for enrollment information.
Where is the NCT05320926 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05320926 clinical trial?
NCT05320926 is sponsored by Yonsei University. The principal investigator is Byeong-Keuk Kim at Severance Cardiovascular Hospital, Yonsei University Health System. The trial plans to enroll 3,744 participants.